Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL PLUS versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL PLUS versus SUDAFED 12 HOUR.
DRIXORAL PLUS vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Antihistamine/Decongestant
Decongestant